Cardinal Health, Inc. (NYSE:CAH) is struggling to gain traction with investors, as evidenced by its 2.76 million shares volume. The daily trading volume average remained 2.2 million shares over the course of 3 months. The stock had opened the regular trading at $65.18 and managed a -0.58% price change to reach $64.7 through the close.Cardinal Health, Inc. (CAH) Analyst Opinion
Cardinal Health, Inc. has a consensus hold rating from 16 Wall Street analysts, and the number of shares currently sold short amount to at least 3.18% of shares outstanding. The stock sank -2.35% last month and is down -10.1 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover CAH having a buy-equivalent rating. Analysts have placed a $72.56 price target on Cardinal Health, Inc., suggesting a 12.15% gain from recent close. It’s currently trading about -23.77% below its 52-week high.
Cardinal Health, Inc. (CAH) surprised the stock market in its last reported earnings when it earned $1.31 a piece versus the consensus-estimated $1.24. Its revenue totaled $32.73 billion up 2.87% from the previous quarter.Cardinal Health, Inc. (NYSE:CAH) Intraday View
This stock (CAH) is ahead of its 52-week low with 3.19%. Its last month’s stock price volatility remained 2.4% which for the week stands at 1.73%. The share price has moved backward from its 20 days moving average, trading at a distance of -2.83% and stays -3.28% away from its 50 days moving average. Over the last five days, shares have faced -1.7% losses and now is down -13.05% since hitting its 200-day moving average of $72.42. Cardinal Health, Inc. (CAH) has made its way to a 12-month decline of -14.56%.
Turning to Five Prime Therapeutics, Inc. (NASDAQ:FPRX), its shares were trading at $46.03 a retreat of $-0.6, on the trading floor. The stock, after opening at $46.79, touched a high of $46.85 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Five Prime Therapeutics, Inc. has 5 buy ratings, 1 holds and 0 sells even after the stock tumbled -24.52% from its high of $60.98 to a $1.33 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1.56 to 1.56 during a month. Analysts set a 12-month price target of $57.44 a share. The target implies a 24.79% spike from where the shares are currently trading. Also, the current price highlights a discount of 104.21% to analysts’ high consensus price target.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday Trading
The counter witnessed a trading volume of 0.39 million shares versus an average volume of 0.32 million shares during last trading session. Its last month’s stock price volatility remained 4.98% which for the week approaches 4.81%. The lowest price the stock reached in the last trading day was $45.01 and compares with the $25.97 52-week low. The stock recovered 77.24% since its low point and has performed -8.14% year-to-date.